Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Not yet recruiting · NCT06922656 · Registry updated 2025-08-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? | Acid-Base Imbalance, Ketosis, Nutritional and Metabolic Diseases, acidosis disorder, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypoglycemia, immune system disorder, metabolic disease, type 1 diabetes mellitus | Not yet recruiting | Phase 4 | 2025-08-29 | NCT06922656 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dasman Diabetes Institute | 8 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dasman Diabetes Institute | Kuwait City | Kuwait | 1 |
| Diabetes and Endocrine Treatment Center, Prince Sultan Military Medical City. Kidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Alfaisal Univeristy, Riyadh, Kingdom of Saudi Arabia | Riyadh | Saudi Arabia | 1 |
| Hamad Medical Corporation | Doha | Qatar | 10 |